- Illumina launches new business to accelerate technology and data-driven . . .
BioInsight, a new business within Illumina, is launched with a dedicated focus on developing data assets, software, and AI solutions to fuel breakthroughs in life sciences
- Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024
Core Illumina revenue of $1 1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4 3 billion for fiscal year
- Illumina addresses recent developments in China - PR Newswire
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4 50 SAN DIEGO, March 10, 2025 PRNewswire -- Illumina, Inc (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the
- Alliance for Genomic Discovery completes 250,000 whole genomes to . . .
Illumina and NashBio announce that the Alliance for Genomic Discovery – a consortium of biotech and biopharma organizations – has completed its initial goal of sequencing 250,000 whole genomes
- Illumina® Protein Prep launches to drive greater proteomic insights for . . .
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program
- Illumina unveils first-of-its-kind spatial transcriptomics technology
PRNewswire -- Illumina, Inc (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and
- Illumina Introduces Multiple Breakthrough Sequencing Innovations at . . .
SAN DIEGO, Sept 29, 2022 PRNewswire -- Illumina, Inc (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing
- Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding . . .
Today the Alliance for Genomic Discovery, led by Illumina and Nashville Biosciences, announced Alnylam Pharmaceuticals has joined the consortia, aimed at accelerating drug discovery fueled by
|